Literature DB >> 7104036

Increased binding of desmethylimipramine in plasma of phenobarbital-treated rats.

M Brinkschulte, U Breyer-Pfaff.   

Abstract

In plasma of untreated male Wistar rats the mean free fraction of desmethylimipramine (DMI) amounted to 10.5%. A five-day oral treatment with phenobarbital (PB) reduced it to 6.2%. A similar effect was produced in female Wistar rats and in male, but not in female Sprague-Dawley rats. Pretreatment with DDT did not alter DMI binding. The PB effect not be attributed to the presence of PB or its metabolites in plasma nor to lower levels of endogenous compounds attached to plasma proteins. Studies on single DMI-binding proteins in plasma of male Wistar rats disclosed unchanged concentrations and binding properties of albumin and total lipoproteins following PB administration, while alpha 1-acid glycoprotein isolated from plasma of PB-treated animals bound DMI stronger than that from controls and contained a higher percentage of N-acetylneuraminic acid. The enhanced binding to a chemically altered alpha 1-acid glycoprotein species is at least one factor responsible for decreased tissue-plasma concentration ratios of DMI in PB-treated rats and constitutes an unusual type of drug interaction.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104036     DOI: 10.1016/0006-2952(82)90679-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

Review 1.  Pharmacokinetic considerations in the treatment of childhood epilepsy.

Authors:  Jamie T Gilman; Michael Duchowny; Ana E Campo
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  Modification of inflammatory processes by phenobarbital in rats.

Authors:  F E Levy; L Chauvelot-Moachon; I Florentin; M Forest; C Poüs; C Fournier; J P Giroud
Journal:  Inflammation       Date:  1991-12       Impact factor: 4.092

4.  Disopyramide pharmacokinetics and metabolism: effect of inducers.

Authors:  R P Kapil; J E Axelson; I L Mansfield; D J Edwards; B McErlane; M A Mason; D Lalka; C R Kerr
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

5.  Alpha 1-acid glycoprotein concentration and serum protein binding of carbamazepine and carbamazepine-10,11 epoxide in children with epilepsy.

Authors:  M Contin; R Riva; F Albani; E Perucca; G Lamontanara; A Baruzzi
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.